285 related articles for article (PubMed ID: 33497525)
1. Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.
Nordén ES; Bendiksen BA; Andresen H; Bergo KK; Espe EK; Hasic A; Hauge-Iversen IM; Veras I; Hussain RI; Sjaastad I; Christensen G; Cataliotti A
ESC Heart Fail; 2021 Apr; 8(2):918-927. PubMed ID: 33497525
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction.
Shi YJ; Yang CG; Qiao WB; Liu YC; Liu SY; Dong GJ
Eur J Pharmacol; 2023 Dec; 961():176170. PubMed ID: 37939991
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
4. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
[TBL] [Abstract][Full Text] [Related]
5. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
[No Abstract] [Full Text] [Related]
6. Study on the Efficacy of Sacubitril/Valsartan in Patients with Heart Failure with Preserved Ejection Fraction Undergoing Peritoneal Dialysis.
Sheng Y; Ma X; Liu Y; Yang X; Sun F
Cardiology; 2023; 148(5):385-394. PubMed ID: 37253340
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
[TBL] [Abstract][Full Text] [Related]
8. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Burke RM; Lighthouse JK; Mickelsen DM; Small EM
Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/Valsartan Averts Adverse Post-Infarction Ventricular Remodeling and Preserves Systolic Function in Rabbits.
Torrado J; Cain C; Mauro AG; Romeo F; Ockaili R; Chau VQ; Nestler JA; Devarakonda T; Ghosh S; Das A; Salloum FN
J Am Coll Cardiol; 2018 Nov; 72(19):2342-2356. PubMed ID: 30384891
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling.
Tam K; Richards DA; Aronovitz MJ; Martin GL; Pande S; Jaffe IZ; Blanton RM
J Card Fail; 2020 Sep; 26(9):769-775. PubMed ID: 32464187
[TBL] [Abstract][Full Text] [Related]
12. Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.
Trivedi RK; Polhemus DJ; Li Z; Yoo D; Koiwaya H; Scarborough A; Goodchild TT; Lefer DJ
J Am Heart Assoc; 2018 Mar; 7(5):. PubMed ID: 29502102
[TBL] [Abstract][Full Text] [Related]
13. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting.
Nordberg Backelin C; Fu M; Ljungman C
ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899
[TBL] [Abstract][Full Text] [Related]
14. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety evaluation of sacubitril/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: A prospective cohort study.
Li X; Zuo C; Chen C; Tian D; Li J; Fan L; Li X; Lv Q
Int J Cardiol; 2023 Jan; 371():244-251. PubMed ID: 36174825
[TBL] [Abstract][Full Text] [Related]
16. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Suematsu Y; Jing W; Nunes A; Kashyap ML; Khazaeli M; Vaziri ND; Moradi H
J Card Fail; 2018 Apr; 24(4):266-275. PubMed ID: 29325796
[TBL] [Abstract][Full Text] [Related]
17. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
Li X; Braza J; Mende U; Choudhary G; Zhang P
Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives.
Gori M; D'Elia E; Senni M
Int J Cardiol; 2019 Apr; 281():158-165. PubMed ID: 30420146
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure.
Feng Z; Wang X; Zhang L; Apaer R; Xu L; Ma J; Li X; Che H; Tang B; Xiong Y; Xia Y; Xiao J; Su X; Wang Y; Dou X; Chen J; Mei L; Xue Z; Kong Y; Li S; Zhang H; Lin T; Wen F; Fu X; Tao Y; Fu L; Li Z; Huang R; Ye Z; He C; Shi W; Liang X; Ke G; Liu S
Blood Purif; 2022; 51(3):270-279. PubMed ID: 34753147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]